首页> 外文期刊>International heart journal >Transcatheter Closure of Large Coronary-Cameral Fistulas Using the Patent Ductus Arteriosus Occluder or Amplatzer Vascular Plugs Focus on Technical Aspects and Long-Term Outcomes
【24h】

Transcatheter Closure of Large Coronary-Cameral Fistulas Using the Patent Ductus Arteriosus Occluder or Amplatzer Vascular Plugs Focus on Technical Aspects and Long-Term Outcomes

机译:使用该专利导管闭塞器或Amplatzer血管插头的经截面闭合大型冠状动脉膜瘘缩小了技术方面和长期结果

获取原文
       

摘要

Transcatheter closure (TCC) has emerged as the first-line treatment for coronary artery fistulas. However, limited data exist regarding the long-term outcomes and technical aspects of this procedure. We aimed to report the long-term outcomes and technical aspects of TCC of large coronary-cameral fistulas (CCFs). All patients with large CCFs who underwent attempted TCC using the patent ductus arteriosus (PDA) occluder or Amplatzer vascular plug (AVP), from June 2002 to December 2017, were retrospectively reviewed. A total of 23 patients with large CCFs underwent attempted TCC using the PDA occluder or AVP. Most CCFs originated from the right coronary artery and drained predominantly into the right heart chamber. Procedural success was achieved in 21 (91.3%) patients. Devices were deployed using the arteriovenous loop in 15, transarterial approach in 4, and arterio-artery loop approach in 2 patients. Procedural complications included coronary spasm in one and side branch occlusion in one patient. Among these 21 patients with successful device implantation, follow-up angiograms or computed tomography angiograms were obtained in 14 (66.7%) patients at a median of 11.0 (range, 9.8-16.3) months. Late complications included thrombosis of residual fistula segment without myocardial infarction (MI) in one, coronary thrombosis resulting in MI in one, and recanalization necessitating re-intervention in one patient. No death and device embolization occurred. TCC of large CCFs using the PDA occluder or AVP is an effective therapy in anatomically suitable candidates, with favorable long-term outcomes. Given that potentially hazardous complications may occur late after the procedure, long-term periodic evaluation is mandatory.
机译:经截管闭合(TCC)已成为冠状动脉瘘的一线治疗。但是,存在关于该程序的长期结果和技术方面的有限数据。我们旨在报告大型冠状动脉剧集(CCFS)的长期结果和技术方面的TCC。追溯审查,所有患有使用该专利导管的大型CCFS的患者,使用该专利导管(PDA)封闭剂或Amplatzer血管插头(AVP)从2017年6月至2017年12月开始审查。共有23例大型CCFS的患者使用PDA封堵器或AVP进行了TCC。大多数CCF源自右冠状动脉,主要排入右心室。在21例(91.3%)患者中取得了程序成功。使用15,在2例患者中使用rerterience环,在4例中,在4例中进行晶振方法进行部署装置。程序并发症包括一个患者的一个和侧支分支闭塞的冠状动脉痉挛。在这21例成功的装置植入患者中,在11.0(范围为9.8-16.3)个月的中位数,在14例(66.7%)患者中获得后续血管造影或计算机断层造影血管造影。晚期并发症包括在没有心肌梗塞(MI)的残留瘘管段的血栓形成,冠状动脉血栓形成,导致mi,并且重组需要在一个患者中重新干预。没有发生死亡和设备栓塞。使用PDA封堵器或AVP的大型CCF的TCC是在解剖学上合适的候选者的有效疗法,具有良好的长期结果。鉴于该程序后可能发生潜在危险的并发症,长期定期评估是强制性的。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号